secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mirum Pharmaceuticals, Inc. (MIRM)
CIK:        0001759425
Form:       8-K
Filed at:   2026-08-05T20:02:41+00:00
Accession:  0001759425-26-000044
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mirum Q2 net product sales $176M, raises FY guidance to $680-700M; volixibat NDA delayed to H1 2027
--------------------------------------------------------------------------------

- Q2 2026 net product sales $176.2M, up 38% YoY; LIVMARLI sales $128.7M (+46% YoY), Bile Acid Medicines $47.5M (+20% YoY).
- Full-year 2026 net product sales guidance raised to $680-700M from prior range.
- Volixibat granted Breakthrough Therapy and Orphan Drug Designations for PSC; pre-NDA meeting recommended Phase 3 study, NDA submission now targeted H1 2027.
- Issued $690M of 0.00% convertible senior notes due 2032; settled $237.2M of 4.00% notes due 2029.
- Cash and investments $561.3M as of June 30, 2026; zilurgisertib PDUFA date Sept 26, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759425/000175942526000044/0001759425-26-000044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759425/000175942526000044/mirm-20260805.htm
  HTML page:      https://secwatch.observer/filing/0001759425-26-000044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer